TCWP’s Novartis NVS Stock Holding History

TCWP’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,211	Closed	-$106K	–	1242
2022 Q1	$106K	Buy	+1,211	New	+$105K	0.02%	337

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

TCWP's NVS Position: Q2 2022 in Review

TCWP sold out of Novartis (NVS) in Q2 2022, closing a stake of 1,211 shares — an estimated $106K sold.

TCWP first reported a position in NVS in Q1 2022 and held it in 1 quarter. The position peaked at $106K in Q1 2022. 1,140 funds tracked by Wall St. Rank hold NVS as of Q2 2022.

TCWP reported no remaining Novartis position as of Q2 2022 after selling out during the quarter.
TCWP sold 1,211 Novartis shares in Q2 2022, an estimated $106K.
TCWP first reported a position in Novartis in Q1 2022 and held it in 1 quarter.
TCWP's Novartis position peaked at $106K in Q1 2022.
1,140 funds tracked by Wall St. Rank held Novartis as of Q2 2022.

Based on TCWP's 13F filing for Q2 2022, filed 15 Aug 2022.